May 23, 2013
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company has been named the 2013 Life Science Firm of the Year by the Tech Council of
(TCM). Vanda was honored at the TCM's 25
Annual Tech Awards Celebration held in
, Maryland. The Tech Awards Celebration recognizes the leaders and innovators in the technology and life science communities in
and the surrounding regions.
"We are deeply honored to receive this recognition from the Tech Council of
Mihael H. Polymeropoulos
, M.D., President and CEO of Vanda. "We are privileged to work in a region that is supportive of our efforts to develop new treatments designed to improve the lives of others."
In selecting Vanda for this award, the TCM recognized Vanda's commitment to address patient needs and the company's work to develop tasimelteon, a circadian regulator, for the treatment of Non-24-Hour Disorder (Non-24). Vanda recently announced positive results in the SET and RESET Phase III efficacy studies for Non-24. Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals. Currently no treatment for Non-24 has been approved by the U.S. Food and Drug Administration (FDA). Vanda is targeting a New Drug Application submission with the FDA for tasimelteon in mid-2013.
About The Tech Council of Maryland
The Tech Council of
(TCM) is the largest technology trade group serving the advanced technology and biotechnology communities of Maryland. TCM's mission is to advocate for the interests of the technology community, further the role of technology in the
economy, and nurture an environment where technology companies can collaborate, grow and succeed. For more information, visit
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda, please visit
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this release are "forward-looking statements" under the securities laws. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.